The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
G | Genito urinary system and sex hormones | |
2
|
G04 | Urologicals | |
3
|
G04C | Drugs used in benign prostatic hypertrophy | |
4
|
G04CA | Alpha-adrenoreceptor antagonists | |
5
|
G04CA04 | Silodosin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 8 mg |
| Active Ingredient |
|---|
|
Silodosin is highly selective for α1A-adrenoreceptors that are primarily located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra. Blockade of these α1A-adrenoreceptors causes smooth muscle in these tissues to relax, thus decreasing bladder outlet resistance, without affecting detrusor smooth muscle contractility. |
| Document | Type | Information Source | |
|---|---|---|---|
| RAPAFLO Capsule | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| SILODYX Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) | |
| UROREC Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.